1. Home
  2. COYA vs RPID Comparison

COYA vs RPID Comparison

Compare COYA & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coya Therapeutics Inc.

COYA

Coya Therapeutics Inc.

HOLD

Current Price

$5.05

Market Cap

102.7M

Sector

Health Care

ML Signal

HOLD

Logo Rapid Micro Biosystems Inc.

RPID

Rapid Micro Biosystems Inc.

HOLD

Current Price

$1.08

Market Cap

84.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COYA
RPID
Founded
2020
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
102.7M
84.8M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
COYA
RPID
Price
$5.05
$1.08
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
4
Target Price
★ $15.21
$6.67
AVG Volume (30 Days)
130.8K
★ 305.0K
Earning Date
11-11-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 2.78
EPS
N/A
★ N/A
Revenue
$7,945,753.00
★ $33,587,000.00
Revenue This Year
N/A
$16.95
Revenue Next Year
$387.14
$17.92
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 123.57
19.74
52 Week Low
$3.71
$1.07
52 Week High
$7.75
$4.94

Technical Indicators

Market Signals
Indicator
COYA
RPID
Relative Strength Index (RSI) 54.14 25.73
Support Level $4.42 N/A
Resistance Level $5.17 $2.18
Average True Range (ATR) 0.28 0.07
MACD 0.03 0.01
Stochastic Oscillator 62.75 16.67

Price Performance

Historical Comparison
COYA
RPID

About COYA Coya Therapeutics Inc.

Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.

About RPID Rapid Micro Biosystems Inc.

Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.

Share on Social Networks: